Following the observation that PD-1 was upregulated in human and experimental lung fibrosis, we showed that low dose pembrolizumab exerted anti-fibrotic properties, as indicated by reduction in Ashcroft score and improvement in respiratory mechanics. The gene discussed is PDCD1; the disease is pulmonary fibrosis.